# Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

> **NCT01758510** · PHASE1 · COMPLETED · sponsor: **Hanyang University Seoul Hospital** · enrollment: 6 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease
- Neuromuscular Disease
- Neurodegenerative Disease
- Central Nervous System Disease

## Interventions

- **GENETIC:** HYNR-CS-Allo

## Key facts

- **NCT ID:** NCT01758510
- **Lead sponsor:** Hanyang University Seoul Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2017-04-10
- **Final completion:** 2017-04-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01758510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01758510, "Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01758510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*